JP2013535487A5 - - Google Patents

Download PDF

Info

Publication number
JP2013535487A5
JP2013535487A5 JP2013523278A JP2013523278A JP2013535487A5 JP 2013535487 A5 JP2013535487 A5 JP 2013535487A5 JP 2013523278 A JP2013523278 A JP 2013523278A JP 2013523278 A JP2013523278 A JP 2013523278A JP 2013535487 A5 JP2013535487 A5 JP 2013535487A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
acceptable salt
compound
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013523278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013535487A (ja
JP6196154B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/046285 external-priority patent/WO2012018829A1/en
Publication of JP2013535487A publication Critical patent/JP2013535487A/ja
Publication of JP2013535487A5 publication Critical patent/JP2013535487A5/ja
Application granted granted Critical
Publication of JP6196154B2 publication Critical patent/JP6196154B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013523278A 2010-08-06 2011-08-02 C型肝炎ウイルス阻害剤の組み合わせ Expired - Fee Related JP6196154B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37139910P 2010-08-06 2010-08-06
US61/371,399 2010-08-06
PCT/US2011/046285 WO2012018829A1 (en) 2010-08-06 2011-08-02 Combinations of hepatitis c virus inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016072377A Division JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Publications (3)

Publication Number Publication Date
JP2013535487A JP2013535487A (ja) 2013-09-12
JP2013535487A5 true JP2013535487A5 (enExample) 2014-09-04
JP6196154B2 JP6196154B2 (ja) 2017-09-13

Family

ID=45559795

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013523278A Expired - Fee Related JP6196154B2 (ja) 2010-08-06 2011-08-02 C型肝炎ウイルス阻害剤の組み合わせ
JP2016072377A Withdrawn JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016072377A Withdrawn JP2016155844A (ja) 2010-08-06 2016-03-31 C型肝炎ウイルス阻害剤の組み合わせ

Country Status (14)

Country Link
US (3) US20120196794A1 (enExample)
EP (1) EP2600835B1 (enExample)
JP (2) JP6196154B2 (enExample)
KR (1) KR101846596B1 (enExample)
CN (2) CN103153280B (enExample)
AU (1) AU2011285890B2 (enExample)
BR (1) BR112013002922A2 (enExample)
CA (1) CA2807589C (enExample)
EA (1) EA022303B1 (enExample)
ES (1) ES2685174T3 (enExample)
IL (1) IL224369B (enExample)
MX (1) MX2013001170A (enExample)
SG (2) SG2014008346A (enExample)
WO (1) WO2012018829A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2014514295A (ja) * 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014006314A2 (pt) * 2011-10-21 2017-04-11 Abbvie Inc métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
PT107925A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C型肝炎ウイルス阻害剤
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9775831B2 (en) 2013-07-17 2017-10-03 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of HCV
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI480272B (zh) * 2008-10-09 2015-04-11 Anadys Pharmaceuticals Inc 藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors

Similar Documents

Publication Publication Date Title
JP2013535487A5 (enExample)
JP2015529652A5 (enExample)
JP2017008088A5 (enExample)
US20130072528A1 (en) Methods for Treating HCV
JP2016508134A5 (enExample)
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
JP2014527061A5 (enExample)
JP2011528713A5 (enExample)
US20130172240A1 (en) Methods for treating hcv
JP2014508804A5 (enExample)
WO2016134054A1 (en) Anti-viral compounds
JP2006511538A5 (enExample)
JP2014148552A5 (enExample)
US20140024613A1 (en) Methods for Treating HCV
WO2017040895A1 (en) Anti-viral compounds
JP2013532714A5 (enExample)
AR116922A1 (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
RU2015101702A (ru) Фармацевтически активные соединения
JP2018521077A5 (enExample)
WO2017040896A1 (en) Anti-viral compounds
JP2009532494A5 (enExample)
JP2015526504A5 (enExample)
CA3070878A1 (en) Combination of midh1 inhibitors and dna hypomethylating agents (hma)
WO2016182935A1 (en) Anti-viral compounds
WO2016182934A1 (en) Anti-viral compounds